Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05375643 · ClinicalTrials.gov registry record · NA
SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
A NA study of Gastrointestinal Cancer and Thoracic Cancer, sponsored by Nadine McCleary, MD, MPH.
- Recruiting
- Registry status
- NA
- Development phase
- 210
- Enrollment target
- 3
- Study locations
NCT05375643: Recruiting NA study of Gastrointestinal Cancer and Thoracic Cancer, sponsored by Nadine McCleary, MD, MPH.
NCT05375643 is a NA study of Gastrointestinal Cancer and Thoracic Cancer that is actively recruiting participants, run by Nadine McCleary, MD, MPH. The registered enrollment target is 210 participants, roughly in line with the 225-participant average among 49 other Gastrointestinal Cancer trials with a reported enrollment target. The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05375643, a NA study of Gastrointestinal Cancer and Thoracic Cancer, is actively recruiting participants, sponsored by Nadine McCleary, MD, MPH.
- RECRUITING
- Registry status
- NA
- Development phase
- 210 participants
- Enrollment target
- 3
- Study locations
Study Summary
SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of the intervention. The intervention is comprised of a patient navigator, text message questionnaire, and informational video.
Primary Outcome
Intervention impact on rate of uptake of genomic testing
Conditions Studied
Interventions
- BEHAVIORAL SURGE
Study Locations (3)
Massachusetts
- Dana Farber Cancer Institute - Boston
- Dana-Farber Cancer Institute at St. Elizabeth's Medical Center - Brighton
- Dana-Farber Cancer Instiute - Merrimack Valley - Methuen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2028-07-30 |
| Phase | NA |
What NCT05375643 shows while recruiting
NCT05375643 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 225-participant average among 49 other Gastrointestinal Cancer trials with a reported enrollment target.
The record links to 3 conditions, with Gastrointestinal Cancer appearing as the primary indexed condition, and to 1 intervention - of which SURGE is the first listed.
NCT05375643 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05375643 about?
NCT05375643 is a clinical study titled "SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)". SURGE aims to increase equity in clinical trial enrollment by addressing barriers to genomic testing, which is increasingly needed to assess precision clinical trial eligibility and access standard precision therapies. The study is an interventional pilot meant primarily to assess the feasibility of...
What is the current status of trial NCT05375643?
This trial is currently recruiting. It is a NA study. The enrollment target is 210 participants. The study started on 2023-04-03. Estimated completion is 2028-07-30.
What conditions does trial NCT05375643 study?
This clinical trial studies the following conditions: Gastrointestinal Cancer, Thoracic Cancer, Hematologic Cancer.
What interventions are being tested in trial NCT05375643?
The interventions under investigation include: SURGE (BEHAVIORAL).
Who is sponsoring clinical trial NCT05375643?
This trial is sponsored by Nadine McCleary, MD, MPH, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05375643 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05375643's enrollment target sits among peer trials
210 13th of 49 higher than 36 of 49 other Gastrointestinal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastrointestinal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
Improving Comprehensive Care of Cancer Patients
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
RECRUITING · NA
-
REmote Symptom COllection to improVE postopeRative Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI